title: Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study.
abstract: BACKGROUND
  Infantile hemangiomas have a dramatic response to propranolol, a nonselective beta-blocker. However, this treatment is not risk-free and many patients are excluded because of respiratory comorbidities. Atenolol is a cardioselective beta-blocker that may have fewer adverse events.
  
  
  OBJECTIVE
  We sought to evaluate the effectiveness of atenolol against propranolol in a noninferiority trial.
  
  
  METHODS
  In all, 23 patients met the inclusion criteria and were randomized to receive either atenolol or propranolol. Thirteen patients were treated with atenolol and 10 with propranolol. Follow-up was made at baseline, 2 weeks, 4 weeks, and then monthly for 6 months.
  
  
  RESULTS
  Patients treated with atenolol had a complete response of 53.8% and 60% with propranolol, respectively. These results were nonsignificant (P = .68). Relevant adverse events were not reported.
  
  
  CONCLUSIONS
  The reduced number of patients could have influenced our results.
  
  
  CONCLUSIONS
  Atenolol appears to be as effective as propranolol. We did not find significant differences between these results or any adverse events.
authors.affiliation: Department of Dermatology, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. Electronic address: alvaroabarzuaaraya@gmail.com.
authors.forename: Alvaro
authors.initials: A
authors.lastname: Ábarzúa-Araya
authors.affiliation: Department of Dermatology, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
authors.forename: Cristián P
authors.initials: CP
authors.lastname: Navarrete-Dechent
authors.affiliation: Department of Pediatric Cardiology, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
authors.forename: Felipe
authors.initials: F
authors.lastname: Heusser
authors.affiliation: Department of Pediatric Cardiology, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
authors.forename: Javiera
authors.initials: J
authors.lastname: Retamal
authors.affiliation: Department of Dermatology, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
authors.forename: María Soledad
authors.initials: MS
authors.lastname: Zegpi-Trueba
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D001262:Atenolol / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D018324:Hemangioma, Capillary / Q000151:congenital / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D011433:Propranolol / Q000008:administration & dosage*; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D001262:Atenolol; D011433:Propranolol
keywords: atenolol; beta-blockers; hemangiomas; propranolol; randomized; treatment; trial